Telomir Pharmaceuticals, Inc. Common Stock Cash Flow Conversion Efficiency
Telomir Pharmaceuticals, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a cash flow conversion efficiency ratio of -0.357x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.77 Million) by net assets ($4.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Telomir Pharmaceuticals, Inc. Common Stock (2021–2025)
Cash flow conversion efficiency of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2025. This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TELO share price today for real-time trading data and today's change.
Telomir Pharmaceuticals, Inc. Common Stock Cash Flow Conversion Ratio Explained
Telomir Pharmaceuticals, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Telomir Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Telomir Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see how much is Telomir Pharmaceuticals, Inc. Common Sto worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DMCC SPECIALITY CHEMICALS LIMITED
NSE:DMCC
|
0.070x |
|
AV Tech Corp
TW:8072
|
-0.020x |
|
PT Net Visi Media Tbk
JK:NETV
|
-0.014x |
|
Semyung Electric Machinery Co.Ltd
KQ:017510
|
0.207x |
|
Tsann Kuen Enterprise Co Ltd
TW:2430
|
0.135x |
|
SANU GOLD CORP.
F:L73
|
-0.112x |
|
ATIF Holdings Limited
NASDAQ:ZBAI
|
-0.033x |
|
Southland Holdings, Inc.
NYSE MKT:SLND
|
-0.073x |
Annual Cash Flow Conversion Efficiency for Telomir Pharmaceuticals, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2025. Review TELO financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $5.91 Million | $-3.69 Million | -0.624x | +92.09% |
| 2024-09-30 | $643.04K | $-5.07 Million | -7.885x | -602.39% |
| 2023-09-30 | $3.44 Million | $-3.86 Million | -1.123x | -324.51% |
| 2022-09-30 | $-937.28K | $-468.66K | 0.500x | -65.19% |
| 2021-09-30 | $-83.13K | $-119.40K | 1.436x | -- |
About Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macu… Read more